Modality
Radioligand
MOA
RAS(ON)i
Target
ALK
Pathway
Hedgehog
Wilms
Development Pipeline
Preclinical
~Jan 2016
→ ~Apr 2017
Phase 1
Jul 2017
→ Jun 2025
Phase 1Current
NCT08793201
1,928 pts·Wilms
2017-07→2025-06·Not yet recruiting
1,928 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-06-0210mo agoInterim· Wilms
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P1
Not yet…
Catalysts
Interim
2025-06-02 · 10mo ago
Wilms
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08793201 | Phase 1 | Wilms | Not yet recr... | 1928 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR | |
| Niralucimab | Ionis | Phase 1 | ALK | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| 180-6098 | Innovent Bio | Phase 1 | ALK |